Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

NCT04807595 · clinicaltrials.gov ↗

COMPLETED

Status

798

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

OTHER: None (Observational study)

Sponsor

AstraZeneca

Collaborators

[object Object]